Conditions: Renal Cancer Kidney Cancer
Keywords: Kidney Cancer Renal Cancer Clear Cell Carcinoma
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 119
Healthy volunteers: no

Brief summary:
This trial will examine the effectiveness and the side effects of 2 higher dosing schedules of bevacizumab in patients that have advanced clear cell renal carcinoma.

Detailed description:
Bevacizumab is considered a targeted drug. Targeted drugs act on specific receptors on a cell. Bevacizumab blocks receptors that help cancer cells develop blood supplies so that the cancer can grow. These specific receptors are found in greater numbers in kidney cancer. In that regard bevacizumab will be tested in 2 doses that are higher than non-kidney cancer treatments with bevacizumab.

One group of patients will receive bevacizumab at 15 mg per kg by vein every 2 weeks. A total of 75 patients will be treated with this dose.

If this dose is well tolerated a second group of patients will receive bevacizumab at 15mg per kg by vein weekly.

Arms:
arm 1: Bevacizumab 15mg/kg IV weekly until progressive disease or toxicity arm 2: Bevacizumab 15mg/kg IV every 2 weeks until progressive disease or toxicity

Interventions: intervention 1: Bevacizumab
Intervention descriptions: intervention 1: Bevacizumab

Protocol document: